Company Insider Sells 376 Shares: Senior Managing Director and General Counsel of $CME

Jonathan L. Marcus, the Senior Managing Director and General Counsel at $CME, recently divested 376 shares of the company on 09-16-2025, amounting to approximately $97,368 based on the data disclosed in a current SEC filing. This transaction represented about 4.2% of their holdings of this particular stock class and reduced their overall ownership to 8,537 shares of $CME stock.

Over the past half-year, insiders at $CME have engaged in 21 trades involving the company’s stock. Among these transactions, 4 were acquisitions, and 17 were sales. Notable movements include Sunil Cutinho, the Chief Information Officer, who made 2 sales of 11,896 shares totaling $3,229,444. Additionally, Derek Sammann, Senior Managing Director of Global Head Commodities Markets, disposed of 4,650 shares for an estimated $1,304,847. Larry G. Gerdes and Charles P. Carey, both active within the company, each conducted 3 sales resulting in $1,060,441 and $950,356 respectively. Phyllis M. Lockett offloaded 1,060 shares amounting to $294,552, while Dennis Suskind divested 1,000 shares with an estimated value of $271,280. Furthermore, Jonathan L. Marcus, in addition to the recent sale, previously sold 766 shares worth approximately $205,593.

Hedge fund activity concerning $CME has shown fluctuations in investor sentiment. By observing 843 institutional investors, it is noticeable that 718 reduced their positions in the last quarter. Notable changes include FMR LLC adding 3,048,375 shares or 305.7% to their portfolio, equivalent to $840,193,117. Conversely, BlackRock, Inc. removed 2,571,288 shares or 7.9% from their holdings, valued at $708,698,398. The firm GQG Partners LLC augmented their portfolio by adding 1,368,647 shares or 62.1%, worth $377,226,486. Other notable entities such as GAMMA INVESTING LLC, MORGAN STANLEY, and CAPITAL WORLD INVESTORS also showed substantial changes in their positions regarding $CME stock.

Political figures, notably members of Congress, have been engaged in trading activities involving $CME stock. Representative Julie Johnson executed 3 trades, comprising 2 purchases with a combined value of up to $30,000 and 1 sale valued at up to $15,000. Representative Val T. Hoyle purchased up to $15,000 worth of shares, while Representative Jefferson Shreve and Representative Robert Bresnahan conducted sales of up to $50,000 and purchases of up to $15,000 respectively.

Financial analysts have issued reports and ratings on $CME in recent times, with 3 firms advocating buying the stock and 2 suggesting selling. Noteworthy ratings include Oppenheimer’s “Outperform,” and Piper Sandler’s “Overweight.” Conversely, analyst reports from Morgan Stanley and JP Morgan issued “Overweight” and “Underweight” ratings, respectively. Additionally, B of A Securities declared an “Underperform” rating for $CME on a recent date.

Various analysts have provided price targets for $CME, with a median target of $285.0 based on estimations from 11 analysts. Noteworthy targets include Alex Kramm from UBS setting a target price of $285.0, Owen Lau from Oppenheimer targeting $303.0, and Benjamin Budish from Barclays aiming for $298.0. Furthermore, Patrick Molley from Piper Sandler proposed a target price of $296.0, and Christopher Allen from Citigroup set a target of $275.0. Lastly, Kenneth Worthington from JP Morgan outlined a target price of $211.0, and Kyle Voigt from Keefe, Bruyette & Woods set a target price of $273.0 for $CME stock.

It is important to note that this article is not intended to be used as financial advice, and for further information and disclaimers, please refer to Quiver Quantitative’s disclosures.